Amgen account plan
Developing innovative human therapeutics
At a glance
Amgen is a biotechnology company making biologic medicines and biosimilars, with $36,751 million of 2025 revenues and about 31,500 staff.
Amgen discovers, develops, manufactures and delivers medicines, mostly biologics, in cardiovascular, bone health, inflammation, rare disease and oncology, and sells its own biosimilars. It operates in one segment, human therapeutics, selling mainly in the United States and Europe and through affiliates and partners in Asia, Latin America and the Middle East. In 2025 total revenues were $36,751 million (+10%), operating income $9,080 million and net income $7,711 million. Amgen had approximately 31,500 staff members in over 50 countries at December 31, 2025, and manufactures mainly in Puerto Rico.
Business units
Prolia (osteoporosis)
about 12.6% of 2025 product sales ($4,414 million)Denosumab for osteoporosis, up 1% in 2025. Patents expired in the U.S. in February 2025 and in select European countries in November 2025; Q2 2026 sales fell 32% to $759 million on biosimilar erosion.
Repatha (cardiovascular)
about 8.6% of 2025 product sales ($3,016 million)PCSK9 inhibitor for LDL cholesterol, up 36% in 2025 and 37% in Q2 2026 to $953 million, helped by a broader FDA label after the VESALIUS-CV trial.
Otezla (psoriasis)
about 6.4% of 2025 product sales ($2,265 million)Oral treatment for psoriasis and psoriatic arthritis, up 7% in 2025; Q2 2026 sales fell 21% on EU generics and price, and Medicare price setting starts in 2027.
ENBREL (inflammation)
about 6.3% of 2025 product sales ($2,226 million)Rheumatoid arthritis and psoriasis treatment in the U.S. and Canada, down 33% in 2025 as net selling price fell 36%; Medicare price setting began in 2026.
EVENITY (osteoporosis)
about 6.0% of 2025 product sales ($2,100 million)Bone builder sold with partners, up 34% in 2025 and 38% in Q2 2026 to $714 million.
XGEVA (bone metastases)
about 5.9% of 2025 product sales ($2,084 million)Same active ingredient as Prolia, down 6% in 2025 and 34% in Q2 2026 under biosimilar competition.
TEPEZZA (thyroid eye disease)
about 5.4% of 2025 product sales ($1,903 million)Acquired with Horizon in October 2023, up 3% in 2025 and 14% in Q2 2026 to $576 million; a subcutaneous formulation is in Phase 3.
BLINCYTO (leukaemia)
about 4.4% of 2025 product sales ($1,559 million)BiTE treatment for B-cell acute lymphoblastic leukaemia, up 28% in 2025 and 23% in Q2 2026.
Nplate (immune thrombocytopenia)
about 4.3% of 2025 product sales ($1,524 million)Up 5% in 2025 and 17% in Q2 2026 to $430 million.
TEZSPIRE (severe asthma)
about 4.2% of 2025 product sales ($1,478 million)U.S. sales, marketed by AstraZeneca outside the U.S.; up 52% in 2025 and 42% in Q2 2026, with Phase 3 trials in COPD and eosinophilic esophagitis.
KYPROLIS (multiple myeloma)
about 4.0% of 2025 product sales ($1,412 million)Down 6% in 2025 on lower volume from increased competition.
Aranesp (anaemia)
about 4.0% of 2025 product sales ($1,389 million)Anaemia treatment sold mainly in Europe, up 4% in 2025.
KRYSTEXXA (chronic gout)
about 3.8% of 2025 product sales ($1,340 million)Horizon product for chronic refractory gout, up 13% in 2025 on volume and price.
Vectibix (colorectal cancer)
about 3.3% of 2025 product sales ($1,175 million)Treatment for metastatic colorectal cancer, up 12% in 2025.
Other products (biosimilars, rare disease, oncology)
about 20.7% of 2025 product sales ($7,263 million)Includes biosimilars such as PAVBLU, MVASI, AMGEVITA and WEZLANA, rare disease medicines UPLIZNA and TAVNEOS, and oncology medicines IMDELLTRA and LUMAKRAS. Up 29% in 2025; biosimilars brought $3 billion of 2025 sales.
Strategic priorities
- Grow through patent expirations
- Amgen says it must grow sales from existing and new products to offset losses of exclusivity; six growth drivers (Repatha, EVENITY, TEZSPIRE, Rare Disease, Innovative Oncology, Biosimilars) grew 26% in Q2 2026 and were nearly 70% of product sales.
- MariTide in obesity
- MariTide, designed for monthly dosing, has 9 ongoing and 3 planned Phase 3 studies, and 2026 capex of approximately $2.6 billion includes preparation for its launch.
- Cardiometabolic portfolio
- Repatha, olpasiran and MariTide are presented as a combined cardiometabolic set; the olpasiran OCEAN(a) outcome study enrolled 7,297 patients.
- Manufacturing expansion in the U.S.
- Amgen opened a drug-substance site in Holly Springs, North Carolina in January 2025, broke ground on a second one and announced expansions in New Albany, Ohio and Puerto Rico.
- AI across the value chain
- Amgen applies AI across discovery, development, manufacturing and access to medicines and recently established a frontier AI laboratory, bringing agentic workflows to discovery research.
- Direct-to-patient access
- AmgenNow offers a simplified lower-cost cash-pay option for Repatha and is being extended to other medicines.
Latest results
In Q2 2026 total revenues rose 10% to $10,054 million, with product sales up 9% on volume, led by Repatha, EVENITY, UPLIZNA, TEZSPIRE, IMDELLTRA and PAVBLU, while Prolia fell 32% and Otezla 21%. Operating income rose 32% to $3,514 million and net income 66% to $2,375 million ($4.37 per diluted share). H1 2026 revenues were $18,672 million (+8%). Amgen raised 2026 guidance to total revenues of $38.2 billion to $39.4 billion and non-GAAP EPS of $22.30 to $23.50.
Investments and deals
- Capital projects
- Capex was $1.9 billion in 2025, and full-year 2026 capital projects are estimated at approximately $2.6 billion, including MariTide launch preparation.
- R&D spending
- R&D was $7,272 million in 2025 (+22%), with $4,281 million on later-stage clinical programs; Q2 2026 R&D rose 7% to $1,868 million, mainly on MariTide.
- Business development
- Business development focuses on the four therapeutic areas, primarily smaller earlier-stage assets; 2026 guidance includes a $100 million upfront in Q3.
- Debt and shareholder returns
- Amgen retired $6.0 billion of debt in 2025, issued $4.0 billion of notes in H1 2026, raised the quarterly dividend 6% to $2.52, and plans buybacks not exceeding $3 billion in 2026.
Challenges and risks
- Biosimilar and generic erosion
- Prolia and XGEVA face accelerated erosion from denosumab biosimilars in 2026, and Otezla faces generics in certain European countries.
- U.S. drug pricing policy
- IRA Medicare price setting (ENBREL from 2026, Otezla from 2027), expanded 340B use, the MFN initiative and CMS's GENEROUS Model weigh on net prices; ENBREL net price fell 22% in Q2 2026.
- IRS tax dispute
- The IRS seeks approximately $3.6 billion plus interest for 2010-2012 and approximately $5.1 billion plus penalties for 2013-2015; a Tax Court decision is expected no earlier than late 2026 or early 2027.
- Pipeline setbacks
- The FDA asked for a voluntary withdrawal of TAVNEOS on January 16, 2026, bemarituzumab will not be filed in first-line gastric cancer, and olpasiran event accrual is lower than initial predictions.
- Manufacturing concentration and supply chains
- Commercial manufacturing is concentrated in Puerto Rico, and conflict in the Middle East has increased volatility in energy and transportation markets and disrupted supply chains.
What leadership says
“once again demonstrate our ability to grow through patent expirations and increased competition”
“a year of disciplined data generation”
“the bar is high at Amgen for obesity medicines”
“the 2 labels really just don't compare”
Where a supplier can help
- Launch readiness for MariTide
- Tied to the MariTide priority and the approximately $2.6 billion capex plan: manufacturing capacity, device assembly and supply chain partners fit launch preparation.
- Clinical trial operations
- Tied to the growing later-stage R&D spend: CROs, trial technology and patient recruitment support the many Phase 3 programmes in obesity, cardiovascular and immunology.
- AI and data for R&D
- Tied to the AI priority: data platforms and AI tools fit the frontier AI laboratory and agentic workflows in discovery research.
- Market access and direct-to-patient
- Tied to the pricing challenge and AmgenNow: patient support, pricing analytics and cash-pay channel services help offset net price pressure.
- Supply chain resilience
- Tied to the manufacturing concentration challenge: logistics and supply risk tools address disruption and the concentration in Puerto Rico.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Amgen?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Annual Report on Form 10-K for fiscal year 2025
- Amgen is a Delaware-incorporated biotechnology company (founded 1980) that discovers, develops, manufactures and sells medicines; it reports one operating segment, human therapeutics, and had approximately 31,500 staff in over 50 countries at December 31, 2025.
- FY2025: total revenues $36,751 million (+10%), product sales $35,148 million (+10%; volume +13%, net selling price -3%), operating income $9,080 million (+25%), net income $7,711 million (+89%), diluted EPS $14.23.
- The U.S. is 73% of product sales ($25,656 million); McKesson, Cencora and Cardinal Health together accounted for 77% of worldwide gross revenues.
- Growth brands: Repatha $3,016 million (+36%), EVENITY $2,100 million (+34%), TEZSPIRE $1,478 million (+52%), BLINCYTO $1,559 million (+28%); ENBREL fell 33% to $2,226 million on lower net price (340B mix, Medicare Part D redesign).
- Patent cliff: RANKL antibody patents for Prolia ($4,414 million, the largest product) and XGEVA expired in the U.S. in February 2025 and in select European countries in November 2025; Amgen expects accelerated sales erosion in 2026 from biosimilars. Otezla is selected for Medicare price setting from 2027 (a $1.2 billion impairment in 2025).
- R&D rose 22% to $7,272 million, driven by Later-Stage Clinical Programs including MariTide (six global Phase 3 studies initiated in 2025); 23 Phase 3 programs as of February 3, 2026.
- Capital: operating cash flow $10.0 billion, capex $1.9 billion (Ohio, North Carolina, Puerto Rico), $6.0 billion of debt retired; long-term debt $50,005 million; quarterly dividend raised 6% to $2.52 for Q1 2026.
- Key risks: U.S. drug pricing (IRA, 340B, MFN executive order; Amgen announced MFN-aligned actions in December 2025), biosimilar and generic competition, an IRS transfer-pricing dispute seeking about $3.6 billion (2010-2012) and $5.1 billion plus $2.0 billion penalties (2013-2015), and manufacturing concentration in Puerto Rico.
- Executive team (as of February 13, 2026): Robert A. Bradway, Chairman and CEO; James E. Bradner, EVP R&D; Murdo Gordon, EVP Global Commercial Operations; Peter H. Griffith, EVP and CFO; Esteban Santos, EVP Operations; David M. Reese, EVP and Chief Technology Officer.
- Quarterly Report on Form 10-Q for the second quarter of 2026
- Q2 2026 (quarter to June 30, 2026): total revenues $10,054 million (+10%), product sales $9,537 million (+9%, driven by volume), operating income $3,514 million (+32%), net income $2,375 million (+66%), diluted EPS $4.37 (vs $2.65).
- H1 2026: total revenues $18,672 million (+8%), product sales $17,755 million (+7%; volume +9%, partially offset by lower net selling price), net income $4,194 million.
- Growth brands in Q2: Repatha $953 million (+37%), EVENITY $714 million (+38%), TEZSPIRE $486 million (+42%), UPLIZNA $335 million (+90%), IMDELLTRA/IMDYLLTRA $288 million (more than doubled), PAVBLU U.S. $280 million.
- Erosion: Prolia $759 million (-32%) and XGEVA $352 million (-34%) on biosimilars; Otezla $491 million (-21%) with generics in some European countries; ENBREL -4% after Medicare Part D price setting took effect on January 1, 2026.
- Cost of sales fell to 28.0% of revenues on lower acquisition amortization; R&D $1,868 million (+7%), driven by MariTide.
- Cash $13,989 million at June 30, 2026 after issuing $4.0 billion of notes; full-year 2026 capex estimated at about $2.6 billion; quarterly dividend $2.52 (+6%).
- Policy: Section 232 tariffs on patented pharmaceuticals imposed in April 2026, but Amgen has relief for about three years from December 2025; CMS's GENEROUS Medicaid model adds supplemental rebates.
- Tax: U.S. Tax Court decision on the 2010-2015 dispute expected no earlier than late 2026 or early 2027; the IRS issued a similar draft notice for 2016-2018 in April 2026.
- Second quarter 2026 earnings conference call (transcript)
- Bob Bradway (Chairman and CEO): total revenues exceeded $10 billion in Q2 2026 (+10%); 22 products grew double digits and 17 annualise above $1 billion; the six key growth drivers grew 26% and were nearly 70% of product sales.
- The six drivers per Murdo Gordon: Repatha +37%, EVENITY +38%, TEZSPIRE +42%, Rare Disease +21% ($1.6 billion), Innovative Oncology +18% (about $2 billion), Biosimilars +29% ($855 million).
- Prolia and XGEVA combined $1.1 billion, -33%, in line with expectations after several biosimilar launches.
- Guidance raised: 2026 total revenues $38.2-39.4 billion and non-GAAP EPS $22.30-23.50; non-GAAP operating margin roughly 45%-46% of product sales; capex about $2.6 billion, partly to scale capacity for MariTide's launch.
- Pipeline (Jay Bradner): MariTide has 9 ongoing and 3 planned Phase 3 studies, aiming for monthly or as few as 4 or 6 doses per year; AMG 513 stopped; olpasiran (Lp(a)) in two Phase 3 outcome studies; dazodalibep Phase 3 results in H2 2026.
- AI: Amgen has set up a frontier AI laboratory in research using agentic workflows.
- Business development: focused on four therapeutic areas, looking "primarily in smaller earlier-stage assets"; a deal with a $100 million upfront lands in Q3 R&D.
- CFO transition: Peter Griffith's last call; Thomas Dittrich takes the CFO role for the next call.
- Fourth quarter and full year 2025 earnings conference call (transcript)
- Bob Bradway (Chairman and CEO) on 2025: 14 products reached sales of $1 billion or more, 13 grew double digits and 18 achieved record results; double-digit growth in revenues and EPS.
- Six areas of momentum for 2026: Repatha, EVENITY and TEZSPIRE (each grew more than 30% in 2025), rare disease (more than $5 billion of 2025 sales), innovative oncology (+11%) and biosimilars ($3 billion of 2025 sales).
- 2026 guidance at the time: total revenues $37 billion to $38.4 billion; Peter Griffith called 2026 a "springboard year", with growth expected to more than offset denosumab biosimilar declines.
- Commercial (Murdo Gordon): Repatha passed $3 billion (+36%); EVENITY $2.1 billion (+34%) with over 60% share of the U.S. bone-builder segment; rare disease nearly $5.2 billion (+14%); innovative oncology $8.7 billion; biosimilars +37% to $3 billion.
- Pricing and access: AmgenNow direct-to-patient cash-pay programme launched for Repatha, to be extended to other medicines, plus TrumpRx availability.
- Pipeline (Jay Bradner): six global Phase 3 studies for MariTide; VESALIUS-CV showed a 25% relative risk reduction; olpasiran outcome event accrual slower than predicted; pivotal UPLIZNA studies in autoimmune hepatitis and CIDP; bemarituzumab and rocatinlimab dropped.
- TAVNEOS: the FDA requested a voluntary withdrawal on January 16, 2026; Bradner said Amgen "were surprised" and is in discussions with the FDA.
- Financials: 2025 non-GAAP operating margin 46%, non-GAAP R&D a record $7.2 billion (+22%), free cash flow $8.1 billion, capex $2.2 billion, $6 billion of debt retired.
Questions about Amgen
What does Amgen do?
Amgen discovers, develops, manufactures and sells medicines, mostly biologics, for cardiovascular disease, osteoporosis, inflammation, rare diseases and cancer, and sells its own biosimilars.
What is Amgen's revenue?
Total revenues were $36,751 million in 2025, up 10%. Amgen guides 2026 total revenues of $38.2 billion to $39.4 billion.
How many employees does Amgen have?
Amgen had approximately 31,500 staff members in over 50 countries at December 31, 2025.
Who leads Amgen?
Robert A. Bradway is Chairman and CEO. Thomas Dittrich succeeds Peter Griffith as CFO, and James Bradner leads R&D.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)